Last edition
News about Clinical Trials
Phase IIa MAST trial of EnteroBiotix’s microbiome therapy EBX-102-02 completes enrolment of 50 patients undergoing allogeneic stem cell transplantation to assess microbiome restoration and transplant outcomes.
Clinical Trials | 12/03/2026 | By News Bureau | 116
IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours
IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.
Clinical Trials | 11/03/2026 | By News Bureau | 221
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
Clinical Trials | 10/03/2026 | By News Bureau | 106
Roche Reports Update on PERSEVERA Breast Cancer Trial
Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.
Clinical Trials | 09/03/2026 | By News Bureau | 102
Dyne Therapeutics Reports Positive Results from Z-Rostudirsen DMD Study
Dyne Therapeutics reported new 24-month data from the DELIVER trial showing Z-rostudirsen improved cardiopulmonary function in patients with Duchenne Muscular Dystrophy (DMD), building on earlier findings of sustained functional benefits across multiple clinical measures.
Clinical Trials | 09/03/2026 | By News Bureau
HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours
HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.
Clinical Trials | 06/03/2026 | By News Bureau
The FDA lifted the clinical hold on Intellia’s phase III MAGNITUDE trial evaluating CRISPR-based therapy nex-z for transthyretin amyloidosis with cardiomyopathy, enabling the company to resume patient enrollment with enhanced safety measures.
Clinical Trials | 05/03/2026 | By News Bureau | 158
Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial
Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.
Clinical Trials | 02/03/2026 | By News Bureau | 164
MindRank Doses First Patient in Phase III Trial of AI-Designed Oral GLP-1RA MDR-001 in China
MindRank has initiated its Phase III MOBILE trial of MDR-001, an AI-designed oral GLP-1 receptor agonist, evaluating long-term efficacy and safety in 750 obesity and type 2 diabetes patients in China.
Clinical Trials | 02/03/2026 | By News Bureau | 285
Johnson & Johnson Submits sBLA to US FDA for IMAAVY in Warm Autoimmune Hemolytic Anemia
Johnson & Johnson has filed a supplemental biologics application seeking US approval of IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia, a rare disorder with no currently approved treatments.
Clinical Trials | 26/02/2026 | By News Bureau | 191
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy